Centessa Pharmaceuticals PLC ADR CNTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
-
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
-
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
-
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
-
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
-
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Trading Information
- Previous Close Price
- $17.20
- Day Range
- $16.04–17.16
- 52-Week Range
- $5.15–17.59
- Bid/Ask
- $14.50 / $17.65
- Market Cap
- $2.09 Bil
- Volume/Avg
- 715,992 / 579,450
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 239.63
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 75
- Website
- https://www.centessa.com
Valuation
|
Metric
|
CNTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.41 |
Price/Sales | 239.63 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNTA
|
|---|---|
Quick Ratio | 12.78 |
Current Ratio | 13.29 |
Interest Coverage | −15.68 |
Quick Ratio
CNTA
Profitability
|
Metric
|
CNTA
|
|---|---|
Return on Assets (Normalized) | −32.97% |
Return on Equity (Normalized) | −48.06% |
Return on Invested Capital (Normalized) | −36.55% |
Return on Assets
CNTA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nhmrtyqm | Ksml | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ccrshtgx | Nbjnwyt | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zltgsxbx | Dthqwsl | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tynxjqmnj | Vpcxgz | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Nrvlnvy | Yfcpq | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Mnqvctnr | Pjrl | $28.3 Bil | |||
| Moderna Inc
MRNA
| Llbjlgsvm | Fyvc | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Vxmxygmtb | Bhdy | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jsvgqbhg | Hlhqlty | $13.3 Bil | |||
| Incyte Corp
INCY
| Vvzkrkt | Zpqklwk | $13.0 Bil |
United States